Alector licenses brain‑penetrant GCase therapy to Genentech, receives $100 M upfront
Alector announced an exclusive global licensing deal with Genentech, a Roche subsidiary, granting Genentech worldwide rights to develop and commercialize AL050, an engineered glucocerebrosidase enzyme delivered via Alector’s Brain Carrier platform for Parkinson’s and other neurodegenerative diseases. Under the agreement Alector will receive a $100 million upfront payment and may earn up to $1.17 billion in milestones plus tiered royalties on net sales. The partnership is expected to extend Alector’s cash runway into 2029 and fund its own pipeline of brain‑enabled antibody and siRNA programs.
Why it matters
The company says the upfront cash and potential milestone payments will extend its cash runway to 2029, giving resources to advance its own pipeline (the company’s statement).
Key facts
- 1Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050. globenewswire.com
- 2Alector will receive a $100 million upfront payment. globenewswire.com
- 3Alector is eligible for up to $1.17 billion in additional milestone payments. globenewswire.com
- 4Alector will receive tiered royalties on net sales of AL050. globenewswire.com
- 5Genentech will handle development, regulatory, manufacturing and commercialization. globenewswire.com
- 6The agreement extends Alector’s cash runway into 2029. globenewswire.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.